IL146508A0 - A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders - Google Patents
A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disordersInfo
- Publication number
- IL146508A0 IL146508A0 IL14650800A IL14650800A IL146508A0 IL 146508 A0 IL146508 A0 IL 146508A0 IL 14650800 A IL14650800 A IL 14650800A IL 14650800 A IL14650800 A IL 14650800A IL 146508 A0 IL146508 A0 IL 146508A0
- Authority
- IL
- Israel
- Prior art keywords
- vla
- treatment
- monoclonal antibody
- inflammatory disorders
- blocking monoclonal
- Prior art date
Links
- 230000000903 blocking effect Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13703899P | 1999-06-01 | 1999-06-01 | |
| US18533600P | 2000-02-29 | 2000-02-29 | |
| PCT/US2000/015004 WO2000072881A1 (en) | 1999-06-01 | 2000-06-01 | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL146508A0 true IL146508A0 (en) | 2002-07-25 |
Family
ID=26834850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14650800A IL146508A0 (en) | 1999-06-01 | 2000-06-01 | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| IL146508A IL146508A (en) | 1999-06-01 | 2001-11-15 | Blocking antibody to vla-1 and its use in the manufacture of a pharmaceutical composition for the treatment of inflammatory disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL146508A IL146508A (en) | 1999-06-01 | 2001-11-15 | Blocking antibody to vla-1 and its use in the manufacture of a pharmaceutical composition for the treatment of inflammatory disorders |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US6955810B2 (cs) |
| EP (3) | EP2314315B1 (cs) |
| JP (6) | JP4817503B2 (cs) |
| CN (1) | CN1309419C (cs) |
| AU (2) | AU783989B2 (cs) |
| BG (1) | BG65579B1 (cs) |
| BR (1) | BR0011250A (cs) |
| CA (1) | CA2375827C (cs) |
| CY (1) | CY1116042T1 (cs) |
| CZ (1) | CZ300710B6 (cs) |
| DK (2) | DK2314315T3 (cs) |
| EA (1) | EA011384B1 (cs) |
| EE (1) | EE200100651A (cs) |
| ES (2) | ES2557768T3 (cs) |
| GE (1) | GEP20063774B (cs) |
| HK (1) | HK1043320A1 (cs) |
| HU (1) | HUP0202568A3 (cs) |
| IL (2) | IL146508A0 (cs) |
| IS (1) | IS6179A (cs) |
| MX (1) | MXPA01012388A (cs) |
| NO (1) | NO20015864L (cs) |
| NZ (1) | NZ515686A (cs) |
| PT (2) | PT2314315E (cs) |
| SI (2) | SI1488806T1 (cs) |
| SK (1) | SK17232001A3 (cs) |
| TR (1) | TR200103432T2 (cs) |
| WO (1) | WO2000072881A1 (cs) |
| YU (1) | YU85501A (cs) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4817503B2 (ja) * | 1999-06-01 | 2011-11-16 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
| CA2443903C (en) | 2001-04-13 | 2018-03-20 | Biogen, Inc. | Antibodies to vla-1 |
| WO2003068262A1 (en) * | 2002-02-14 | 2003-08-21 | Biogen, Inc. | Alpha1beta1 antagonists for treatment of atherosclerosis |
| EA200500576A1 (ru) * | 2002-11-01 | 2006-02-24 | Бойз Таун Нэшнл Рисерч Хоспитал | ИНДУЦИБЕЛЬНЫЙ ЛИГАНД ИНТЕГРИНА α1β1 И ПРИМЕНЕНИЯ |
| WO2005004800A2 (en) * | 2003-06-20 | 2005-01-20 | Morehouse School Of Medicine | Trypanosome derived apoptotic factors (taf) |
| WO2005057755A1 (en) * | 2003-12-09 | 2005-06-23 | Electrotechnologies Selem, Inc. | Polyphase claw-pole machines with a segmented magnetic circuit |
| US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| WO2006124269A2 (en) * | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| WO2006133286A2 (en) * | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
| AU2007267579B2 (en) | 2006-05-25 | 2013-05-30 | Biogen Ma Inc. | Methods of treating stroke |
| AU2009245724A1 (en) * | 2008-05-09 | 2009-11-12 | Ablynx N.V. | Amino acid sequences directed against integrins and uses thereof |
| EP2582391B1 (en) * | 2010-06-18 | 2018-10-03 | XBiotech, Inc | Arthritis treatment |
| EP2670438A4 (en) * | 2011-02-03 | 2015-05-20 | Santarus Inc | SELECTION AND TREATMENT OF PATIENTS |
| CN104271122A (zh) | 2012-02-16 | 2015-01-07 | 桑塔鲁斯股份有限公司 | 抗vla1(cd49a)抗体药物组合物 |
| MA49645A (fr) | 2017-07-20 | 2021-03-31 | Univ Virginia Patent Foundation | Procédés de traitement ou de prévention d'un trouble neurologique du système immunitaire |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5391481A (en) * | 1990-08-31 | 1995-02-21 | The Trustees Of Columbia University | Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| DE69309044T3 (de) | 1992-01-13 | 2004-12-23 | Biogen, Inc., Cambridge | Behandlung von asthma |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
| EP0678122B1 (en) | 1993-01-12 | 1999-07-28 | Biogen, Inc. | Recombinant anti-vla4 antibody molecules |
| JP3593343B2 (ja) | 1993-02-09 | 2004-11-24 | バイオジェン インコーポレイテッド | インシュリン依存型糖尿病の治療 |
| US6111598A (en) | 1993-11-12 | 2000-08-29 | Peveo, Inc. | System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| DK1759709T3 (da) | 1994-01-25 | 2013-06-10 | Elan Pharm Inc | Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4 |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| DE69518415T2 (de) | 1994-04-26 | 2001-01-25 | Kanebo, Ltd. | Arznei für rheumatoide arthritis |
| JPH08131185A (ja) * | 1994-11-14 | 1996-05-28 | Sumitomo Electric Ind Ltd | マウスｖｌａ−１分子に対するモノクローナル抗体 |
| JPH08160972A (ja) | 1994-12-01 | 1996-06-21 | Sega Enterp Ltd | エフェクト制御方法、制御装置およびこれを利用したカラオケ装置 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9516399D0 (en) | 1995-08-10 | 1995-10-11 | Camelot Superabsorbents Ltd | Process for the production of water-absorbing compositions |
| JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質／（ポリ）ペプチドライブラリー |
| DK0843961T3 (da) | 1995-08-29 | 2007-05-21 | Kirin Brewery | Kimærisk mus og fremgangsmåde til at producere samme |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| GB9519667D0 (en) | 1995-09-27 | 1995-11-29 | Univ Manchester | Pharmaceutical composition |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| FR2745912B1 (fr) * | 1996-03-08 | 1998-05-29 | Lorraine Laminage | Procede et dispositif de controle de la soudabilite de toles sandwich |
| US6127524A (en) | 1996-10-18 | 2000-10-03 | Dade Behring Inc. | Binding molecules and computer-based methods of increasing the binding affinity thereof |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| EP1079843B1 (en) | 1998-05-22 | 2007-04-18 | Boys Town National Research Hospital | Use of alfa1beta1 integrin receptor inhibitors and tgf- beta1 inhibitors in the treatment of kidney disease |
| DE19831710A1 (de) | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
| EP1119583A1 (en) | 1998-10-06 | 2001-08-01 | Biogen, Inc. | Crystals of the alpha 1 beta 1 integrin i-domain and their use |
| KR20070102760A (ko) * | 1999-04-22 | 2007-10-19 | 바이오겐 아이덱 엠에이 인코포레이티드 | 인테그린 알파-4 서브유닛의 길항 물질을 사용하는섬유증의 치료 방법 |
| JP4817503B2 (ja) | 1999-06-01 | 2011-11-16 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
| JP2003502094A (ja) | 1999-06-17 | 2003-01-21 | デジンガー カイ | 侵害を最小限にした組織採取のための外科用ゾンデ |
| WO2001073444A2 (en) | 2000-03-28 | 2001-10-04 | Cambridge University Technical Services Limited | Receptor/peptide crystal structure for identification of inhibitors |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| DE10028402A1 (de) | 2000-06-13 | 2001-12-20 | Merck Patent Gmbh | Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate |
| US7153944B2 (en) | 2000-07-31 | 2006-12-26 | The General Hospital Corporation | High affinity integrin polypeptides and uses thereof |
| CA2443903C (en) | 2001-04-13 | 2018-03-20 | Biogen, Inc. | Antibodies to vla-1 |
| WO2003068262A1 (en) | 2002-02-14 | 2003-08-21 | Biogen, Inc. | Alpha1beta1 antagonists for treatment of atherosclerosis |
| WO2004013180A2 (en) | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| US20040208870A1 (en) | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
| WO2005019200A2 (en) | 2003-08-14 | 2005-03-03 | Icos Corporation | Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof |
| WO2005016883A2 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Acrylamide derivatives as vla-1 integrin antagonists and uses thereof |
| US7285530B2 (en) | 2004-10-21 | 2007-10-23 | Viron Therapeutics, Inc. | Use of SERP-1 as an antiplatelet agent |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| WO2006133286A2 (en) | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| AU2007267579B2 (en) | 2006-05-25 | 2013-05-30 | Biogen Ma Inc. | Methods of treating stroke |
| JP4951596B2 (ja) | 2008-07-31 | 2012-06-13 | 株式会社日立製作所 | 冷却システム及び電子装置 |
| PE20120359A1 (es) | 2009-03-06 | 2012-04-13 | Genentech Inc | Formulacion con anticuerpo |
| CN107095846A (zh) | 2009-12-21 | 2017-08-29 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| EP2670438A4 (en) | 2011-02-03 | 2015-05-20 | Santarus Inc | SELECTION AND TREATMENT OF PATIENTS |
| EP2804208A4 (en) | 2012-01-11 | 2015-07-29 | Panasonic Ip Man Co Ltd | PRESSURE CONTACT SEMICONDUCTOR DEVICE AND METHOD FOR THE PRODUCTION THEREOF |
| CN104271122A (zh) | 2012-02-16 | 2015-01-07 | 桑塔鲁斯股份有限公司 | 抗vla1(cd49a)抗体药物组合物 |
-
2000
- 2000-06-01 JP JP2000620987A patent/JP4817503B2/ja not_active Expired - Lifetime
- 2000-06-01 ES ES04018151.3T patent/ES2557768T3/es not_active Expired - Lifetime
- 2000-06-01 HK HK02105185.2A patent/HK1043320A1/zh unknown
- 2000-06-01 YU YU85501A patent/YU85501A/sh unknown
- 2000-06-01 PT PT10185467T patent/PT2314315E/pt unknown
- 2000-06-01 NZ NZ515686A patent/NZ515686A/en unknown
- 2000-06-01 GE GE5125A patent/GEP20063774B/en unknown
- 2000-06-01 IL IL14650800A patent/IL146508A0/xx active IP Right Grant
- 2000-06-01 EP EP10185467.7A patent/EP2314315B1/en not_active Expired - Lifetime
- 2000-06-01 SI SI200031089T patent/SI1488806T1/sl unknown
- 2000-06-01 ES ES10185467.7T patent/ES2529706T3/es not_active Expired - Lifetime
- 2000-06-01 CZ CZ20014249A patent/CZ300710B6/cs not_active IP Right Cessation
- 2000-06-01 EP EP04018151.3A patent/EP1488806B1/en not_active Expired - Lifetime
- 2000-06-01 CN CNB008084289A patent/CN1309419C/zh not_active Expired - Lifetime
- 2000-06-01 EE EEP200100651A patent/EE200100651A/xx unknown
- 2000-06-01 EP EP00942654A patent/EP1181054A1/en not_active Withdrawn
- 2000-06-01 TR TR2001/03432T patent/TR200103432T2/xx unknown
- 2000-06-01 AU AU57248/00A patent/AU783989B2/en not_active Expired
- 2000-06-01 CA CA2375827A patent/CA2375827C/en not_active Expired - Lifetime
- 2000-06-01 EA EA200400930A patent/EA011384B1/ru not_active IP Right Cessation
- 2000-06-01 BR BR0011250-0A patent/BR0011250A/pt not_active Application Discontinuation
- 2000-06-01 DK DK10185467.7T patent/DK2314315T3/en active
- 2000-06-01 SK SK1723-2001A patent/SK17232001A3/sk unknown
- 2000-06-01 HU HU0202568A patent/HUP0202568A3/hu unknown
- 2000-06-01 MX MXPA01012388A patent/MXPA01012388A/es active IP Right Grant
- 2000-06-01 PT PT40181513T patent/PT1488806E/pt unknown
- 2000-06-01 DK DK04018151.3T patent/DK1488806T3/en active
- 2000-06-01 WO PCT/US2000/015004 patent/WO2000072881A1/en not_active Ceased
- 2000-06-01 SI SI200031087T patent/SI2314315T1/sl unknown
-
2001
- 2001-11-15 IL IL146508A patent/IL146508A/en not_active IP Right Cessation
- 2001-11-28 IS IS6179A patent/IS6179A/is unknown
- 2001-11-30 NO NO20015864A patent/NO20015864L/no not_active Application Discontinuation
- 2001-11-30 US US09/996,738 patent/US6955810B2/en not_active Expired - Lifetime
- 2001-12-17 BG BG106226A patent/BG65579B1/bg unknown
-
2005
- 2005-04-18 US US11/108,581 patent/US7462353B2/en not_active Expired - Lifetime
-
2006
- 2006-04-12 AU AU2006201540A patent/AU2006201540A1/en not_active Abandoned
-
2007
- 2007-05-22 JP JP2007136041A patent/JP2007277253A/ja active Pending
-
2008
- 2008-11-11 US US12/268,459 patent/US8084031B2/en not_active Expired - Fee Related
-
2011
- 2011-05-24 JP JP2011116366A patent/JP5623335B2/ja not_active Expired - Lifetime
- 2011-11-15 US US13/296,778 patent/US8557240B2/en not_active Expired - Fee Related
-
2012
- 2012-06-07 JP JP2012130177A patent/JP2012176983A/ja active Pending
-
2013
- 2013-09-09 US US14/021,547 patent/US9902774B2/en not_active Expired - Fee Related
-
2014
- 2014-08-18 JP JP2014165702A patent/JP5960762B2/ja not_active Expired - Lifetime
-
2015
- 2015-02-20 CY CY20151100186T patent/CY1116042T1/el unknown
-
2016
- 2016-03-24 JP JP2016060029A patent/JP2016121184A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL146508A0 (en) | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders | |
| IL165193A (en) | Humanized immunomodulatory monoclonal antibodies and use thereof for the treatment of neoplastic disease | |
| GB2368796B (en) | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies | |
| TWI367102B (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
| NO962571D0 (no) | Sanitetsbind med innvendig formgivningskomponent | |
| FI951304A7 (fi) | Muodostusvälineillä varustettu terveysside | |
| IL139217A0 (en) | Monoclonal antibodies to the human ldl receptor, their production and use | |
| EP1085906A4 (en) | ANTIBODIES AGAINST CYTOKINS FOR THE PREVENTION AND TREATMENT OF INFLAMMABLE INTESTINAL DISEASES | |
| PL325457A1 (en) | Humanised antibodies effective against human fas | |
| FR2747911B3 (fr) | Agrafe asymetrique monobloc a deux branches convergentes pour l'osteosynthese des fractures | |
| DE69509987D1 (de) | Eingerollte Monatsbinde | |
| ZA200109273B (en) | A blocking monoclonal antibody to VLA-1 and its use for the treatment of inflammatory disorders. | |
| NO20012612D0 (no) | Isonipecotamider for behandling av integren-formidlede lidelser | |
| HUP0200354A3 (en) | Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases | |
| GB9901682D0 (en) | Therapeutic antibody composition and use | |
| GB9907151D0 (en) | Therapeutic antibody composition and use | |
| GB9901689D0 (en) | Therapeutic antibody composition and use | |
| GB9906754D0 (en) | Therapeutic antibody composition and use | |
| GB9923551D0 (en) | Treatment of neuropsychiatric disorders | |
| GB9823943D0 (en) | Therapeutic antibody composition and use | |
| TW389292U (en) | Structure for preventing the internal tube of tape faucet from being twisted and flipped | |
| GB9419312D0 (en) | Polyclonal antibodies and their use | |
| GEP20043233B (en) | Composition Containing Blocking Monoclonal Antibody VLA-1 | |
| GB0029955D0 (en) | Treatment of neuropsychiatric disorders | |
| GB0016824D0 (en) | Human monoclonal antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |